Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 1
2004 1
2005 1
2006 2
2007 2
2008 5
2009 3
2010 8
2011 3
2012 8
2013 12
2014 18
2015 16
2016 21
2017 27
2018 37
2019 32
2020 32
2021 43
2022 22
Text availability
Article attribute
Article type
Publication date

Search Results

250 results
Results by year
Filters applied: . Clear all
Page 1
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Górriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjöström CD, Langkilde AM, Heerspink HJL. Wheeler DC, et al. Among authors: cherney dzi. Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234. Nephrol Dial Transplant. 2020. PMID: 32862232 Free PMC article. Clinical Trial.
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cannon CP, et al. Among authors: cherney dzi. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966714 Clinical Trial.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Bhatt DL, et al. Among authors: cherney dzi. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200891 Clinical Trial.
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Heerspink HJL, et al. Among authors: cherney dzi. Kidney Int. 2018 Jul;94(1):26-39. doi: 10.1016/j.kint.2017.12.027. Epub 2018 May 5. Kidney Int. 2018. PMID: 29735306 Free article. Review.
Preventing CKD in Developed Countries.
Luyckx VA, Cherney DZI, Bello AK. Luyckx VA, et al. Among authors: cherney dzi. Kidney Int Rep. 2019 Dec 18;5(3):263-277. doi: 10.1016/j.ekir.2019.12.003. eCollection 2020 Mar. Kidney Int Rep. 2019. PMID: 32154448 Free PMC article. Review.
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP. McGuire DK, et al. Among authors: cherney dzi. JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511. JAMA Cardiol. 2021. PMID: 33031522 Free PMC article.
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Cherney DZI, et al. Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Lancet Diabetes Endocrinol. 2020. PMID: 32559474 Clinical Trial.
250 results